Úskalí laboratorních metod v ovariálním skríninku - doba "-omická"?
| Title in English | Obstacles of the laboratory screening methods - the "-omic" era? |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Onkologie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.onkologiecs.cz/artkey/xon-202002-0005_uskali_laboratornich_metod_v_ovarialnim_skrininku_-_doba_-omicka.php |
| Doi | http://dx.doi.org/10.36290/xon.2020.016 |
| Keywords | gynaecologic onkology; ovarian carcinoma; screening; vascular endothelial growth factor VEGF; glycomics |
| Description | Up to date publications have always considered ovarian carcinoma to be an unpreventable disease. Respectively there has not been yet identified a screening method or a combination of methods for population application. Herewith we are presenting the history of laboratory methods and their present use. This is our introduction of the results of two pilot studies. First, we examined the serum levels of vascular endothelial growth factor VEGF D to be a potential biomarker of early ovarian carcinoma with interesting data. Second pilot study presents the results of measurement of specific glycan profiles in association with resistance to platinum chemotherapy and to the overall survival. Biomarker CA 125 cannot be used as a population screening method, as we have explained. The interpretation of the elevated levels of CA 125 is confusing. For the future biomarker we expect not only high sensitivity and specificity rate. Ideally, we plan this biomarker itself or in combination to predict the specific therapeutic method for the patient with potentially best results for overall survival. |